Evidence map›Paper›PMID 40076679›Full record

ReviewInternational journal of molecular sciences2025

Living Bacteria: A New Vehicle for Vaccine Delivery in Cancer Immunotherapy.

Min Yang, Peiluan Zhong, Pengcheng Wei

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Review
  3. Microbial medicines: Unlocking the therapeutic potential of the microbiome in cancer treatment.Journal of controlled release : official journal of the Controlled Release Society · 2026
    Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. EngineeredInternational journal of nanomedicine · 2025
    Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Min YangGuangxi Key Laboratory of Special Biomedicine, School of Medicine, Guangxi University, Nanning 530004, China.ORCID 0000-0003-4792-9493
Peiluan ZhongGuangxi Key Laboratory of Special Biomedicine, School of Medicine, Guangxi University, Nanning 530004, China.ORCID 0009-0002-2682-895X
Pengcheng WeiGuangxi Key Laboratory of Special Biomedicine, School of Medicine, Guangxi University, Nanning 530004, China.ORCID 0000-0003-0002-9439

Funding

Guangxi Green Seedling Talent Program ZX02080033724001Guangxi Natural Science Foundation 2024GXNSFBA010423, 2023GXNSFAA026039Guangxi University Science and Technology Multiplication Program for Cultivating Young Back-bone Innovative Talents 2023BZRC014
6 · The paper itself

Abstract

Cancer vaccines, aimed at evolving the human immune system to eliminate tumor cells, have long been explored as a method of cancer treatment with significant clinical potential. Traditional delivery systems face significant challenges in directly targeting tumor cells and delivering adequate amounts of antigen due to the hostile tumor microenvironment. Emerging evidence suggests that certain bacteria naturally home in on tumors and modulate antitumor immunity, making bacterial vectors a promising vehicle for precision cancer vaccines. Live bacterial vehicles offer several advantages, including tumor colonization, precise drug delivery, and immune stimulation, making them a compelling option for cancer immunotherapy. In this review, we explore the mechanisms of action behind living bacteria-based vaccines, recent progress in popular bacterial chassis, and strategies for specific payload delivery and biocontainment to ensure safety. These approaches will lay the foundation for developing an affordable, widely applicable cancer vaccine delivery system. This review also discusses the challenges and future opportunities in harnessing bacterial-based vaccines for enhanced therapeutic outcomes in cancer treatment.

Indexed as

BacteriaCancer VaccinesImmunotherapyNeoplasmsAnimalsDrug Delivery SystemsHumansTumor MicroenvironmentCancer Vaccinesbacteriacancer vaccineimmunotherapyvaccine delivery

Identifiers

PMID40076679
PMCPMC11900161

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.